{
    "root": "c3d774f4-3240-4803-bf7e-1712e302c83b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ZEPBOUND",
    "value": "20250312",
    "ingredients": [
        {
            "name": "tirzepatide",
            "code": "OYN3CCI6QE"
        },
        {
            "name": "Sodium Phosphate, Dibasic, Heptahydrate",
            "code": "70WT22SF4B"
        },
        {
            "name": "Sodium Chloride",
            "code": "451W47IQ8X"
        },
        {
            "name": "Hydrochloric Acid",
            "code": "QTT17582CB"
        },
        {
            "name": "Sodium Hydroxide",
            "code": "55X04QC32I"
        },
        {
            "name": "Water",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "zepbound® indicated combination reduced-calorie diet increased physical activity : reduce excess body weight maintain weight reduction long term adults obesity adults overweight presence least one weight-related comorbid condition . treat moderate severe obstructive sleep apnea ( osa ) adults obesity .",
    "contraindications": "recommended dose escalation schedule recommended starting 2.5 mg injected subcutaneously weekly 4 weeks . increase 2.5 mg increments least 4 weeks recommended maintenance achieved . ( 2.1 ) consider treatment response tolerability selecting maintenance . ( 2.1 ) recommended maintenance maximum weight reduction long-term maintenance : 5 mg , 10 mg , 15 mg injected subcutaneously weekly . ( 2.2 ) obstructive sleep apnea : 10 mg 15 mg injected subcutaneously weekly . ( 2.2 ) maximum recommended : 15 mg injected subcutaneously weekly . ( 2.2 ) instructions full prescribing information instructions . ( 2.4 )",
    "warningsAndPrecautions": "zepbound ( tirzepatide ) clear , colorless slightly yellow solution available cartons containing 4 pre-filled single-dose pens , 1 single-dose vial , 4 single-dose vials follows : total strength per total volume 4 pack pen ndc 1 pack vial ndc 4 packvial ndc 2.5 mg/0.5 ml 0002-2506-80 0002-0152-01 0002-0152-04 5 mg/0.5 ml 0002-2495-80 0002-0243-01 0002-0243-04 7.5 mg/0.5 ml 0002-2484-80 0002-1214-01 0002-1214-04 10 mg/0.5 ml 0002-2471-80 0002-1340-01 0002-1340-04 12.5 mg/0.5 ml 0002-2460-80 0002-1423-01 0002-1423-04 15 mg/0.5 ml 0002-2457-80 0002-2002-01 0002-2002-04",
    "adverseReactions": "zepbound contraindicated patients : personal family history mtc patients men 2 [ ( 5.1 ) ] . known serious hypersensitivity tirzepatide excipients zepbound . serious hypersensitivity , including anaphylaxis angioedema , reported tirzepatide [ ( 5.6 ) ( 6.2 ) ] .",
    "indications_original": "ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity:\n\n                  \n                     to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.\n\n                     \n                        to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.",
    "contraindications_original": "Recommended Dose Escalation Schedule The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks. Increase the dosage in 2.5 mg increments after at least 4 weeks until recommended maintenance dosage is achieved. ( 2.1 ) Consider treatment response and tolerability when selecting the maintenance dosage. ( 2.1 ) Recommended Maintenance and Maximum Dosage Weight Reduction and Long-Term Maintenance: 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly. ( 2.2 ) Obstructive Sleep Apnea: 10 mg or 15 mg injected subcutaneously once weekly. ( 2.2 ) Maximum Recommended Dosage: 15 mg injected subcutaneously once weekly. ( 2.2 ) Administration Instructions See full prescribing information for administration instructions. ( 2.4 )",
    "warningsAndPrecautions_original": "ZEPBOUND (tirzepatide) is a clear, colorless to slightly yellow solution available in cartons containing 4 pre-filled single-dose pens, 1 single-dose vial, or 4 single-dose vials as follows:\n\n                        \n                           \n                           \n                           \n                           \n                           \n                              \n                                 \n                                    Total Strength per Total Volume\n                                 \n                                 \n                                    4 pack\n                                    \n                                       \n                                    \n                                    Pen NDC\n                                 \n                                 \n                                    1 pack\n                                    \n                                       \n                                    \n                                    Vial NDC\n                                 \n                                 \n                                    4 packVial NDC\n                                 \n                              \n                              \n                                 2.5 mg/0.5 mL\n\n                                 0002-2506-80\n\n                                 0002-0152-01\n\n                                 0002-0152-04\n\n                              \n                              \n                                 5 mg/0.5 mL\n\n                                 0002-2495-80\n\n                                 0002-0243-01\n\n                                 0002-0243-04\n\n                              \n                              \n                                 7.5 mg/0.5 mL\n\n                                 0002-2484-80\n\n                                 0002-1214-01\n\n                                 0002-1214-04\n\n                              \n                              \n                                 10 mg/0.5 mL\n\n                                 0002-2471-80\n\n                                 0002-1340-01\n\n                                 0002-1340-04\n\n                              \n                              \n                                 12.5 mg/0.5 mL\n\n                                 0002-2460-80\n\n                                 0002-1423-01\n\n                                 0002-1423-04\n\n                              \n                              \n                                 15 mg/0.5 mL\n\n                                 0002-2457-80\n\n                                 0002-2002-01\n\n                                 0002-2002-04",
    "adverseReactions_original": "ZEPBOUND is contraindicated in patients with:\n\n                  \n                     A personal or family history of MTC or in patients with MEN 2 [see Warnings and Precautions (5.1)].\n\n                     Known serious hypersensitivity to tirzepatide or any of the excipients in ZEPBOUND. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide [see Warnings and Precautions (5.6) and Adverse Reactions (6.2)]."
}